# EFFICIENT SYNTHESIS AND BIOLOGICAL PROPERTIES OF 6-ARYL-10-CHLORO-8-IODO-12*H*-[1,8] NAPHTHYRIDINO [2,1-*b*] QUINAZOLIN-12-ONES

K. Mogilaiah\*, P. Koteswara Rao and A. Nageswara Rao

Department of Chemistry, Kakatiya University, Warangal-506 009 E-mail: mogilaiah\_k@yahoo.co.in

Received 8 July 2015; Accepted 13 Nov. 2015

A simple and efficient, method for the synthesis of 6-aryl-10-chloro-8-iodo-12*H*-[1,8] naphthyridino [2,1-*b*] quinazolin-12-ones **3** by the cyclocondensation of 3-aryl-2-chloro-1,8-naphthyridines **1** with methyl 2-amino-5-chloro-3- iodobenzoate **2** in the presence of catalytic amount of DMF under microwave irradiation has been described. The yields are very good and purity is high. The structural assignments of compounds **3** were based on their elemental analyses and spectral (IR <sup>1</sup>H NMR and MS) data. Compounds **3** have been screened for their antibacterial and anti-inflammatory activities.

1,8-Naphthyridines are important biological agents and a significant amount of research activity has been directed towards this class. In particular, they are used as antibacterial1, antiinflammatory2 and antitumor3 agents. Quinazolines have received great attention from synthetic and biological point of view<sup>4-6</sup>. Therefore, it was envisaged that chemical entities with both 1,8naphthyridine and quinazoline might result in compounds with interesting biological activity. The microwave-induced organic reactions are becoming popular because of their simplicity and operational convenience7-9. Solvent-free microwave-assisted chemical reactions8 are gaining importance due to the advantages and environmentally friendly processes they offer, as compared to conventional reactions. In view of this and in continuation of our interest in microwave-assisted organic transformations of 1,8naphthyridine derivatives 10-12, we present herein, a simple and efficient method for the synthesis of 6aryl-10-chloro-8-iodo-12*H*-[1,8] naphthyridino [2,1-b] quinazolin-12-ones 3 in solvent-free conditions under microwave irradiation and also evaluation of their antibacterial and anti-inflammatory properties.

Cyclocondensation of 3-aryl-2-chloro-1,8-naphthyridines **1** with methyl 2-amino-5-chloro-3-iodobenzoate **2** in the presence of catalytic amount of DMF without any solvent under microwave irradiation afforded the corresponding 6-aryl-10-chloro-8-iodo-12*H*-[1,8] naphthyridino [2,1-*b*] quinazolin-12-ones **3** (Scheme-1), in very good yields (92-96%) with short reaction time (2.0-3.0 min). The products were

obtained with a high degree of purity by this procedure. The process is environmentally friendly. The experimental procedure is very simple. It was observed that the neat mixtures of **1** and **2** did not reacted under microwave irradiation, but the reaction proceeds to completion within minutes on addition of few drops of high dielectric solvent such as DMF.

In a typical experimental procedure, equimolar quantities of 2-chloro-3-phenyl-1,8-naphthyridine 1a, methyl 2-amino-5-chloro-3-iodobenzoate 2 and catalytic amount of DMF was exposed to microwave irradiation at 400 watts intermittently for 30 sec intervals for 2.5 min. The reaction mixture was cooled to RT, digested with cold water and filtered off. After usual work-up 10-chloro-8-iodo-6-phenyl 12*H*-[1,8] naphthyridino [2,1-*b*] quinazolin-12-one 3a was obtained in 93% yield. The reaction is of general applicability and the various 6-aryl-10-chloro-8-iodo-12*H*-[1,8] naphthyridino [2,1-*b*] quinazolin-12-ones 3 synthesized are given in Table-1.

The reaction proceeds to only 6-8% in 2.0-3.0 min, when conducted under conventional conditions in an oil-bath preheated to 120° (measured immediately after microwave irradiation), thus demonstrating the advantage of the microwave heating method.

The structures of the compounds **3** were determined by spectral (IR, <sup>1</sup>H NMR and MS) and analytical data. The experimental simplicity, high yields, short reaction times, excellent purity and

Table-1 Physical data of compounds **3** 

Compd	Ar	Reaction time (min)	M.P. (°C)	Yield (%)	
3a	$C_6H_5$	2.5	178	93	
3b	4-CH <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	3.0	210	95	
3c	4-CH <sub>3</sub> OC <sub>6</sub> H <sub>4</sub>	3.0	165	93	
3d	2-CI-C <sub>6</sub> H <sub>4</sub>	2.5	218	94	
3e	3-CIC <sub>6</sub> H <sub>4</sub>	2.0	228	92	
3f	4-CIC <sub>6</sub> H <sub>4</sub>	2.5	221	96	
3g	2-FC <sub>6</sub> H <sub>4</sub>	2.5	232	93	
3h	3-FC <sub>6</sub> H <sub>4</sub>	3.0	205	92	
3i	4-FC <sub>6</sub> H <sub>4</sub>	3.0	238	95	
3j	3-BrC <sub>6</sub> H <sub>4</sub>	2.5	224	92	
3k	4-BrC <sub>6</sub> H <sub>4</sub>	3.0	168	94	
31	2-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	2.5	213	93	
3m	3-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	2.0	226	92	
3n	4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub>	3.0	208	95	
30	2-Naphthyl	3.0	143	94	

All the compounds gave satisfactory C,H,N elemental analysis

absence of solvent are the advantages of this method and thus, the method is environmentally benign.

# **Antibacterial activity**

All the title compounds **3** were evaluated for their antibacterial activity against Gram-negative *Escherichia coli* and Gram-positive *Bacillus subtilis* using filter paper disc method of Vincent and Vincent<sup>13</sup> at 250 and 500 µg/disc concentrations. Gentamycin was used as standard for comparison. Compounds **3b**, **3d**, **3f**, **3i** and **3n** showed promising antibacterial activity.

## **Anti-inflammatory activity**

All the title compounds **3** were tested for their anti-inflammatory activity by applying carrageenan-induced rat paw edema method<sup>14</sup>, using Diclofenac sodium as reference drug for comparison. Compounds **3b**, **3f**, **3i** and **3n** exhibited significant anti-inflammatory activity at 4th hr.

## **Experimental**

Melting points were determined on a Cintex melting point apparatus and are uncorrected. Homogeneity of the compounds was checked by precoated TLC plates (Merck, 60F-254). IR spectra were recorded in KBr on a Shimadzu FTIR-8400S spectrophotometer, ¹H NMR spectra on a Varian Gemini 400 MHz spectrometer using TMS as internal standard and mass spectra on a VG170708H spectrometer. Microanalyses were performed on a Perkin-Elmer 240 CHN elemental analyzer. Microwave irradiation was carried out in a domestic microwave oven (LG MG 556P, 2450 MHz). The methyl 2-amino-5-chloro-3-iodobenzoate 2 was purchased from Aldrich Chemical Company.

# 6-Aryl-10-chloro-8-iodo-12*H*-[1,8] naphthyridino [2,1-*b*] quinazolin-12-ones : General procedure

A mixture of 3-aryl-2-chloro-1,8-naphthyridine 1 (0.01 mol), methyl 2-amino-5-chloro-3-iodobenzoate 2 (0.01 mol) and DMF (5 drops) was subjected to microwave irradiation at 400 watts intermittently at 30 sec intervals for the specified time (Table-1). On completion of reaction as indicated by TLC, the reaction mixture was allowed to attain RT and digested with cold water. The separated solid was filtered, washed with water and purified by recrystallization from methanol to furnish 3 (Table-1).

#### Spectral data

**3**a : IR (KBr): 1651 (C=O), 1602 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.72 (m, 2H, C<sub>2</sub>-H, C<sub>5</sub>-H), 7.80 (s, 1H, C<sub>10</sub>-H), 7.83 (s, 1H, C<sub>11</sub>-H), 7.96 (m, 1H, C<sub>4</sub>-H), 8.72 (m, 1H, C<sub>2</sub>-H), 7.15-7.62 (m, 5H, ArH); MS (ESI): m/z 484 [M+H]<sup>+</sup>.

**3**b : IR (KBr): 1655 (C=O), 1602 (C=N);  $^{1}$ H NMR (CDCl<sub>3</sub>): 2.40 (s, 3H, CH<sub>3</sub>), 7.62 (m, 2H, C<sub>3</sub>-H, C<sub>5</sub>-H), 7.72 (s, 1H, C<sub>10</sub>-H), 7.80 (s, 1H, C<sub>11</sub>-H), 7.90 (m, 1H, C<sub>4</sub>-H), 8.65 (m, 1H, C<sub>2</sub>-H), 7.12-7.35 (m, 4H, ArH); MS (ESI): m/z 498 [M+H]<sup>+</sup>.

**3**c: IR (KBr): 1663 (C=O), 1605 (C=N);  $^{1}$ H NMR (CDCl<sub>3</sub>): 3.85 (s, 3H, OCH<sub>3</sub>), 7.65 (m, 2H, C<sub>3</sub>-H, C<sub>5</sub>-H), 7.74 (s, 1H, C<sub>10</sub>-H), 7.82 (s, 1H, C<sub>11</sub>-H), 7.95 (m, 1H, C<sub>4</sub>-H), 8.62 (m, 1H, C<sub>2</sub>-H), 6.75-7.22 (m, 4H, ArH); MS (ESI): m/z 514 [M+H]<sup>+</sup>.

**3**d: IR (KBr): 1653 (C=O), 1603 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.68 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.78 (s, 1H,  $C_{10}$ -H), 7.84 (s, 1H,  $C_{11}$ -H), 7.93 (m, 1H,  $C_4$ -H), 8.60 (m, 1H,  $C_2$ -H), 7.16-7.43 (m, 4H, ArH); MS (ESI): m/z 518 [M+H]<sup>+</sup>.

**3**e: IR (KBr): 1658 (C=O), 1602 (C=N); <sup>1</sup>H NMR (CDCI<sub>3</sub>): 7.66 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.80 (s, 1H,  $C_{10}$ -H), 7.86 (s, 1H,  $C_{11}$ -H), 7.97 (m, 1H,  $C_4$ -H), 8.68 (m, 1H,  $C_2$ -H), 7.15-7.45 (m, 4H, ArH); MS (ESI): m/z 518 [M+H]<sup>+</sup>.

**3**f: IR (KBr): 1673 (C=O), 1605 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.62 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.75 (s, 1H,  $C_{10}$ -H), 7.85 (s, 1H,  $C_{11}$ -H), 7.95 (m, 1H,  $C_4$ -H), 8.63 (m, 1H,  $C_7$ -H), 7.18-7.40 (m, 4H, ArH); MS (ESI): 518 [M+H]<sup>+</sup>.

**3**g: IR (KBr): 1672 (C=O), 1603 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.67 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.78 (s, 1H,  $C_{10}$ -H), 7.83 (s, 1H,  $C_{11}$ -H), 7.92 (m, 1H,  $C_4$ -H), 8.58 (m, 1H,  $C_2$ -H), 7.08-7.32 (m, 4H, ArH); MS (ESI): m/z 502 [M+H]<sup>+</sup>.

**3**h: IR (KBr): 1669 (C=O), 1604 (C=N); <sup>1</sup>H NMR (CDCI<sub>3</sub>): 7.75 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.82 (s, 1H,  $C_{10}$ -H), 7.87 (s, 1H,  $C_{11}$ -H), 7.96 (m, 1H,  $C_4$ -H), 8.62 (m, 1H,  $C_2$ -H), 7.20-7.55 (m, 4H, ArH); MS (ESI): m/z 502 [M+H]<sup>+</sup>.

 $\begin{array}{l} \textbf{3} \text{i}: \text{IR (KBr): } 1673 \text{ (C=O), } 1602 \text{ (C=N); } ^{1}\text{H NMR} \\ \text{(CDCI}_{3}\text{): } 7.72 \text{ (m, 2H, C}_{3}\text{-H, C}_{5}\text{-H), } 7.80 \text{ (s, 1H, C}_{10}\text{-H), } \\ 7.85 \text{ (s, 1H, C}_{11}\text{-H), } 7.98 \text{ (m, 1H, C}_{4}\text{-H), } 8.65 \text{ (m, 1H, C}_{2}\text{-H), } 7.15\text{-} 7.48 \text{ (m, 4H, ArH); MS (ESI): m/z } 502 \\ \text{[M+H]}^{+}. \end{array}$ 

**3**j: IR (KBr): 1671 (C=O), 1601 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.76 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.84 (s, 1H,  $C_{10}$ -H), 7.90 (s, 1H,  $C_{11}$ -H), 8.00 (m, 1H,  $C_4$ -H), 8.64 (m, 1H,  $C_2$ -H), 7.20-7.57 (m, 4H, ArH); MS (ESI): m/z 562 [M+H]<sup>+</sup>.

**3**k: IR (KBr): 1658 (C=O), 1604 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.74 (m, 2H,  $C_2$ -H,  $C_5$ -H), 7.88 (s, 1H,  $C_{10}$ -H), 7.93 (s, 1H,  $C_{11}$ -H), 8.03 (m, 1H,  $C_4$ -H), 8.70 (m, 1H,  $C_2$ -H), 7.16-7.50 (m, 4h, ArH); MS (ESI): m/z 562 [M+H]<sup>+</sup>.

**3**I: IR (KBr): 1670 (C=O), 1605 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.70 (m, 2H, C<sub>3</sub>-H, C<sub>5</sub>-H), 7.80 (s, 1H, C<sub>10</sub>-H), 7.95 (s, 1H, C<sub>11</sub>-H), 8.00 (m, 1H, C<sub>4</sub>-H), 8.66 (m, 1H, C<sub>2</sub>-H), 7.18-7.74 (m, 4H, ArH); MS (ESI): m/z 552 [M+H] $^+$ .

**3**m: IR (KBr): 1663 (C=O), 1606 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.65 (m, 2H,  $C_3$ -H,  $C_5$ -H), 7.76 (s, 1H,  $C_{10}$ -H), 7.90 (s, 1H,  $C_{11}$ -H), 8.02 (m, 1H,  $C_4$ -H), 8.62 (m, 1H,  $C_2$ -H), 7.20-7.58 (m, 4H, ArH); MS (ESI): m/z 552 [M+H]<sup>+</sup>.

 $\begin{array}{l} \textbf{3} \text{n: IR (KBr): } 1672 \text{ (C=O), } 1604 \text{ (C=N); } ^{1}\text{H NMR} \\ \text{(CDCI}_{3}\text{): } 7.68 \text{ (m, 2H, C}_{3}\text{-H, C}_{5}\text{-H), } 7.78 \text{ (s, 1H, C}_{10}\text{-H),} \\ 7.86 \text{ (s, 1H, C}_{11}\text{-H), } 7.98 \text{ (m, 1H, C}_{4}\text{-H), } 8.72 \text{ (m, 1H, C}_{2}\text{-H), } 7.16\text{-}7.45 \text{ (m, 4H, ArH); MS (ESI): } \text{m/z } 552 \\ \text{[M+H]}^{+}\text{.} \end{array}$ 

**3**o : IR (KBr): 1659 (C=O), 1600 (C=N); <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.90 (m, 2H,  $C_3$ -H,  $C_5$ -H), 8.25 (s, 1H,  $C_{10}$ -H), 8.30 (s, 1H,  $C_{11}$ -H), 8.20 (m, 1H,  $C_4$ -H), 8.58 (m, 1H,  $C_2$ -H), 7.22-7.68 (m, 7H, ArH); MS (ESI): m/z 534 [M+H]<sup>+</sup>.

# Acknowledgement

The authors are thankful to the Director, IICT, Hyderabad for providing <sup>1</sup>H NMR and mass spectra. Two of them (PKR and ANR) are grateful to CSIR, New Delhi for the award of Senior Research Fellowships.

### References

- C.Y. Hong, Y.K. Kim, J.H. Chang, S.H. Kim, H. Choi, D.H. Nam, Y.Z. Kim and J.H. Kwak, *J. Med. Chem.*, 40 (1997), 3584.
- G. Roma, M.D. Bracci, G. Grassi, D. Piras, V. Ballabeni, M. Tognolini, S. Bertoni and E. Barocelli, Eur. J. Med. Chem., 45 (2010), 352.
- C. Manera, G. Saccomanni, B. Adinolfi, V. Benetti, A. Ligresti, M.G. Cascio, T. Tuccinardi, V. Luccheri, A. Martinelli, P. Nieri, E. Masini, V.D. Marzo and P.L. Ferrarini, *J. Med. Chem.*, 52 (2009), 3644.
- T.P. Tran, E.L. Ellsworth, M.A. Stier, J.M. Domagala, H.D.H. Showalter, S.J. Gracheck, M.A. Shapiro, T.E. Joannides and R. Singh, Bioorg. Med. Chem. Lett., 14 (2004), 4405.
- 5. J. He, X. Wang, X. Zhao, Y. Liang, H. He and L. Fu, *Eur. J. Med. Chem.*, **54** (2012), 925.
- 6. A. Sharma, V. Luxami and K. Paul, *Bioorg. Med. Chem. Lett.*, **23** (2013), 3288.
- 7. S. Caddick, *Tetrahedron*, **51** (1995), 10403.
- 8. A. Loupy, A. Petit, J. Hamelin, F. Texier-Boullet, P. Jacquault and D. Mathe, *Synthesis* (1998), 121.
- 9. P. Lidstrom, J. Tierney, B. Wathey and J. Westman, *Tetrahedron*, **57** (2001), 9225.
- 10. K. Mogilaiah, D. Praveena and A. Aara, *Indian J. Heterocyclic Chem.*, **23** (2014), 261.
- 11. K. Mogilaiah, P. K. Rao and A.N. Rao, *Indian J. Heterocyclic Chem.*, **24** (2014), 153.
- 12. K. Mogilaiah, D. Praveena, S. Jyothi and A.N. Rao, *Indian J. Heterocyclic Chem.*, **24** (2015), 315.
- 13. J.C. Vincent and H.W. Vincent, *Proc. Soc. Exptl. Biol. Med.*, **55** (1944), 162.
- 14. C.A. Winter, E.A. Risely and G.W. Nuss, *Proc. Soc. Exp. Biol. Med.*, **111** (1962), 544.

3348/2015